Hsieh Wen-Hui, Liao Shu-Wei, Chan Shun-Ming, Hou Jin-De, Wu Szu-Yuan, Ho Bing-Ying, Chen Kung-Yen, Tai Yu-Ting, Fang Hsu-Wei, Fang Chih-Yuan, Chen Se-Yi, Lin Jui-An
Department of Chemical Engineering and Biotechnology, National Taipei University of Technology, Taipei 10608, Taiwan, R.O.C.
Department of Anesthesiology, Chi-Mei Medical Center, Tainan 71004, Taiwan, R.O.C.
Oncol Lett. 2023 Jun 27;26(2):346. doi: 10.3892/ol.2023.13932. eCollection 2023 Aug.
The effects of clinically relevant concentrations of lidocaine on epithelial-mesenchymal transition (EMT) and associated lung cancer behaviors have rarely been investigated. The aim of the present study was to assess the impact of lidocaine on EMT and its related phenomena, including chemoresistance. Lung cancer cell lines (A549 and LLC.LG) were incubated with various concentrations of lidocaine, 5-fluorouracil (5-FU) or both to test their effects on cell viability. Subsequently, the effects of lidocaine on various cell behaviors were assessed and using Transwell migration, colony-formation and anoikis-resistant cell aggregation assays, and human tumor cell metastasis in a chorioallantoic membrane (CAM) model quantitated by PCR analysis. Prototypical EMT markers and their molecular switch were analyzed using western blotting. In addition, a conditioned metastasis pathway was generated through Ingenuity Pathway Analysis. Based on these measured proteins (slug, vimentin and E-cadherin), the molecules involved and the alteration of genes associated with metastasis were predicted. Of note, clinically relevant concentrations of lidocaine did not affect lung cancer cell viability or alter the effects of 5-FU on cell survival; however, at this dose range, lidocaine attenuated the 5-FU-induced inhibitory effect on cell migration and promoted EMT. The expression levels of vimentin and Slug were upregulated, whereas the expression of E-cadherin was downregulated. EMT-associated anoikis resistance was also induced by lidocaine administration. In addition, portions of the lower CAM with a dense distribution of blood vessels exhibited markedly increased expression 24 h following the inoculation of lidocaine-treated A549 cells on the upper CAM. Thus, at clinically relevant concentrations, lidocaine has the potential to aggravate cancer behaviors in non-small cell lung cancer cells. The phenomena accompanying lidocaine-aggravated migration and metastasis included altered prototypical EMT markers, anoikis-resistant cell aggregation and attenuation of the 5-FU-induced inhibitory effect on cell migration.
临床相关浓度的利多卡因对上皮-间质转化(EMT)及相关肺癌行为的影响鲜有研究。本研究旨在评估利多卡因对EMT及其相关现象(包括化疗耐药性)的影响。将肺癌细胞系(A549和LLC.LG)与不同浓度的利多卡因、5-氟尿嘧啶(5-FU)或两者共同孵育,以测试它们对细胞活力的影响。随后,通过Transwell迁移、集落形成和抗失巢凋亡细胞聚集试验评估利多卡因对各种细胞行为的影响,并通过PCR分析定量检测人肿瘤细胞在鸡胚绒毛尿囊膜(CAM)模型中的转移情况。使用蛋白质免疫印迹法分析典型的EMT标志物及其分子开关。此外,通过Ingenuity Pathway Analysis生成条件性转移途径。基于这些测得的蛋白质(Snail、波形蛋白和E-钙黏蛋白),预测参与转移的分子以及与转移相关基因的改变。值得注意的是,临床相关浓度的利多卡因不影响肺癌细胞活力,也不改变5-FU对细胞存活的影响;然而,在此剂量范围内,利多卡因减弱了5-FU诱导的对细胞迁移的抑制作用,并促进了EMT。波形蛋白和Snail的表达水平上调,而E-钙黏蛋白的表达下调。利多卡因给药还诱导了与EMT相关的抗失巢凋亡能力。此外,在将利多卡因处理的A549细胞接种到上侧CAM 24小时后,下侧CAM中血管密集分布的部分显示出明显增加的表达。因此,在临床相关浓度下,利多卡因有可能加重非小细胞肺癌细胞的癌症行为。利多卡因加重迁移和转移所伴随的现象包括典型EMT标志物的改变、抗失巢凋亡细胞聚集以及5-FU诱导的对细胞迁移抑制作用的减弱。